Triage is not fun, but even with infinite money it is still necessary, and with finite money it has to be coldly pragmatic.
So NICE has a standard limit of £20,000 per QALY, or up to £30,000 per QALY, if certain extenuating conditions are met.
A QALY being: "A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health. QALYs are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a zero to 1 scale). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance."
If NICE determines that a drug isn't cost-effective, no one gets it (unless you pay out of pocket), regardless if it would have helped that individual patient.
This is not a knock against the UK or US healthcare systems at all.
What worries me about this type of thinking is that you're looking at the cost/benefit in the aggregate. Of course, when you're running a national health system you have to. However, this is also happening in the US (the biggest US insurance companies cover 30M+ lives).
You can describe the cost/benefits overall, but it's (mostly) impossible to at the individual level. Sure the average overall survival for an expensive cancer drug might only be 6 months, but if you look at the data you'd likely see that the range if 15 days to 3 years.
Health authorities might make the call that 6 months of additional life isn't work $XX,XXX dollars, but for some of the patients whose life is extended 2-3 years, it certainly is worth it. But in the end, the call is made to not fund the drug.
I have no idea how to solve this issue. I think linking outcome with genetic information is super helpful (it's already being used), but dam, there are a lot of folks out there that could have been helped, but won't be.